BioMarin SaysVials from Genzyme's Plant Not Expected to Impact Aldurazyme or Naglazyme

BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today that Genzyme (Nasdaq: GENZ) notified the company that, in rare circumstances, it has detected foreign particles in some products filled at the Allston Landing facility. To ensure that patients are not exposed to foreign particles during product administration, Genzyme has issued a "Dear Doctor" letter to all physicians treating patients with enzyme replacement products that it markets, including Aldurazyme.

The letter states that foreign particles have been found in some vials filled at Genzyme's Allston Landing facility and reminds physicians, as a preventive measure, to use a 0.2-0.22 micron filter during administration.